A recent study found significant reductions in opioid overdose and alcohol misuse among people taking GLP-1 drugs like ...

The lawsuit singles out Pivotal Peptides, MangoRx and Genesis Lifestyle Medicine for either offering research-grade meds ...

Eli Lilly sued three medical spas and online vendors for selling products that claim to contain the ingredient in its weight-loss medicine Zepbound.

Clinical and other trials for GLP-1 therapies have found an association between these drugs and diabetic retinopathy ...

In a reversal, the FDA is reconsidering its decision to end the shortage status of tirzepatide, after a recent lawsuit and intense public pressure, The Washington Post reported Oct. 21.

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as ...

Eli Lilly sues medical spas and vendors for selling unauthorized tirzepatide, the active ingredient in its weight-loss drug, Zepbound ... and promotion of products that imitate Mounjaro and Zepbound.

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, ...

Shortages of tirzepatide, sold as a diabetes drug (Mounjaro) and a weight-loss medication (Zepbound), have fueled demand for compounding pharmacies to make their own versions of the medicine, which ...

Rapid weight loss from the glucagon-like peptide 1 (GLP-1s) can reduce fat tissue in face that makes for a smooth, more ...

The Health Secretary has said offering weight loss jabs to unemployed obese people is not “dystopian”. Wes Streeting said a trial to test if anti-obesity injections can increase employment and ease ...

[Editor’s note: While we refer specifically to Ozempic within this piece, these practices may generally apply to the use of all drugs within the weight loss injectable category, such as Mounjaro, a ...